Belli S, Esposito D, Ascione CM, Messina F, et al. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer. Cancer Lett 2024 May 22:216968. doi: 10.1016/j.canlet.2024.216968.
PMID: 38788968